Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasms 4Breast Neoplasms 4Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Ovarian Neoplasms 2Osteosarcoma 2Neuroblastoma 2Lymphoma, Mantle-Cell 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neutropenia 1Neurofibrosarcoma 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroectodermal Tumors, Primitive 1Multiple Myeloma 1Microphthalmia, Isolated, with Coloboma 5 1Melanoma 1Medulloblastoma 1Lymphoma, T-Cell, Peripheral 1

Interventions

Filgrastim 7Peripheral Blood Stem Cell Transplantation 4Melphalan 4Etoposide 4Carboplatin 4Busulfan 4Ifosfamide 3Granulocyte Colony-Stimulating Factor 3tanespimycin 2Thiotepa 2Temozolomide 2Mesna 2Docetaxel 2Cyclophosphamide 2trioctyl phosphine oxide 1temsirolimus 1sargramostim 1pegfilgrastim 1omburtamab I-131 1montanide ISA 51 1ixabepilone 1ganitumab 1entinostat 1cixutumumab 1amino-acid, glucose, and electrolyte solution 1alvocidib 1aldesleukin 1Valproic Acid 1Transplantation 1Topotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neuroectodermal Tumors, Primitive, Peripheral × pegfilgrastim × Clear all
NCT01585649 2016-05-18

PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1 Completed
21 enrolled
Sarcoma

Rhabdomyosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡